We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App

BioFire Diagnostics’ PCR-based SARS-CoV-2 Test Receives FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 08 Oct 2020
Print article
Image: BioFire Respiratory Panel 2.1-EZ (Photo courtesy of BioMérieux)
Image: BioFire Respiratory Panel 2.1-EZ (Photo courtesy of BioMérieux)
BioMérieux’s (Marcy-l'Étoile, France) subsidiary, BioFire Diagnostics, has received Emergency Use Authorization by the US Food and Drug Administration for the BioFire Respiratory Panel 2.1-EZ which uses a syndromic approach to accurately detect and identify a wide range of pathogens, including SARS-CoV-2.

The BioFire RP2.1-EZ Panel is designed to run on the CLIA-waived BioFire FilmArray 2.0 EZ Configuration System and identifies a menu of 19 respiratory targets in one multiplex PCR test, with results in about 45 minutes. Because a large number of pathogens cause respiratory infections, tests that only identify SARS-CoV-2 or influenza run the risk of missing the real culprit. With the ability to identify 15 viral and 4 bacterial respiratory pathogens, BioFire’s easy-to-use syndromic test requires just one nasopharyngeal swab and two minutes of hands-on time. The multiplex PCR BioFire RP2.1-EZ Panel provides a rapid, accurate, and comprehensive alternative to targeted testing and detects a greater number of pathogens no matter the season or the time of year.

Given the shift toward value-based care, BioFire’s syndromic testing can help reduce untimely and expensive send-out tests. The BioFire RP2.1-EZ Panel (EUA) can help reduce overall workload for urgent care clinics, helping streamline workflow, maximize throughput, decrease costs, and increase patient satisfaction.

Related Links:

Print article
BIOHIT  Healthcare OY


Molecular Diagnostics

view channel
Image: Photomicrograph of histology of a Ewing sarcoma in lung. The PAS stain highlights glycogen and the staining was negative with a PAS diastase stain (Photo courtesy of Nephron).

Comprehensive Molecular Profiling Matches Pediatric Patients to Therapies

A major challenge of using a comprehensive profiling approach for precision medicine is separating pathogenic from non-pathogenic molecular changes within a tumor. A program has been presented of the... Read more

Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.